Elsevier

Obstetrics & Gynecology

Volume 87, Issue 2, February 1996, Pages 306-309
Obstetrics & Gynecology

Clinical commentary
An inevitable dilemma: Prenatal testing for mutations in the brca1 breast-ovarian cancer susceptibility gene**

https://doi.org/10.1016/0029-7844(95)00405-XGet rights and content

The BRCA1 breast-ovarian cancer susceptibility gene was identified recently. Germline mutations in BRCA1 may be responsible for as many as 5% of breast and ovarian cancers. Inherited alterations confer up to a 94% risk of developing breast and/or ovarian cancer by age 70. With the discovery of BRCA1, there will be a heavy demand for genetic testing. Because of the large size of the gene and the distribution of reported mutations, scientists face considerable technical problems in developing widely available screening tests; clinicians will face even greater ethical problems in applying them. In the context of research programs, women with BRCA1 mutations are already being identified, and their physicians are confronted with a number of complex medical, ethical, legal, and social issues. Obstetricians will be faced with counseling parents regarding prenatal testing for specific BRCA1 mutations. Although it is difficult to formulate straightforward guidelines regarding prenatal BRCA1 testing, clinicians and health care providers must be familiar with the nuances of the debate so that these issues can be discussed wisely with patients. As with many ethically challenging problems in medicine, individual clinicians and their patients will have to work together to determine the course of action with which they are most comfortable. Although elective termination of a pregnancy with a germline mutation in BRCA1 is an option, experience with other adultonset diseases suggests that only a minority of parents will choose this option.

References (19)

  • FordD et al.

    Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium

    Lancet

    (1994)
  • MikiY et al.

    A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1

    Science

    (1994)
  • Shattuck-EidensM et al.

    A collaborative survey of 80 mutations in the BRCA1 breast, ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening

    JAMA

    (1995)
  • EastonDF et al.

    The Breast Cancer Linkage Consortium. Breast and ovarian cancer incidence in BRCA1-mutation carriers

    Am J Hum Genet

    (1995)
  • WoosterR et al.

    Localization of a breast cancer susceptibility gene BRCA2, to chromosome 13ql2-13

    Science

    (1994)
  • SavitskyK et al.

    A single ataxia telangiectasia gene with a product similar to PI-3 kinase

    Science

    (1995)
  • LiFP et al.

    Recommendations on predictive testing for germ line p53 mutations among cancer-prone individuals

    J Natl Cancer Inst

    (1992)
  • HogervorstFBL et al.

    Rapid detection of BRCA1 mutations by the protein trunction test

    Nature Genetics

    (1995)
  • HoskinsKF et al.

    Assessment and counseling for women with a family history of breast cancer

    JAMA

    (1995)
There are more references available in the full text version of this article.

Cited by (0)

**

Supported in part by National Institutes of Health grant CA55640 (AB).

View full text